School of Pharmaceutical Sciences and Medical Technology, Putian University, Putian, China.
Department of Internal Medicine, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan.
Ann Med. 2022 Dec;54(1):1956-1965. doi: 10.1080/07853890.2022.2096919.
This meta-analysis aimed to assess the usefulness of colchicine in patients with COVID-19.
PubMed, Web of Science, Ovid MEDLINE, the Cochrane Library, Embase, and Clinicaltrials.gov were searched for relevant randomised controlled trials (RCTs) published between database inception and November 12, 2021. Only RCTs that compared the clinical efficacy and safety of colchicine with other alternative treatments or placebos in patients with COVID-19 were included.
Overall, 7 RCTs involving 16,024 patients were included; 7,794 patients were in the study group receiving colchicine and 8,230 were in the control group receiving placebo or standard treatment. The study and control groups had similar risk of mortality (odds ratio [OR], 1.00; 95% CI, 0.91-1.09; = 0%). No significant difference was observed between the study and control groups in terms of the need for non-invasive ventilation (OR, 0.92; 95% CI, 0.83-1.03; = 0%), the need for mechanical ventilation (OR, 0.64; 95% CI, 0.32-1.32; = 58%), and length of hospital stay (mean difference, -0.42 days; 95% CI, -1.95 to 1.11; = 62%). In addition, colchicine was associated with significantly higher risks of gastrointestinal adverse events (OR, 1.81; 95% CI, 1.56-2.11; = 0%) and diarrhoea (OR, 2.12; 95% CI, 1.75-2.56; = 9%).
Colchicine does not improve clinical outcomes in patients with COVID-19, so it did not support the additional use of colchicine in the treatment of patients with COVID-19.Key messageColchicine could not reduce the mortality of patients with COVID-19.No significant difference was observed between the colchicine and comparators in terms of the need for non-invasive ventilation, need for mechanical ventilation, and length of hospital stay.Colchicine was associated with a higher risk of gastrointestinal adverse events.
本荟萃分析旨在评估秋水仙碱在 COVID-19 患者中的作用。
检索了 PubMed、Web of Science、Ovid MEDLINE、Cochrane 图书馆、Embase 和 Clinicaltrials.gov 数据库，以获取 2021 年 11 月 12 日数据库建立以来发表的相关随机对照试验（RCT）。仅纳入比较 COVID-19 患者中使用秋水仙碱与其他替代治疗或安慰剂的临床疗效和安全性的 RCT。
共纳入 7 项 RCT，涉及 16024 例患者；7794 例患者在秋水仙碱组，8230 例患者在安慰剂或标准治疗对照组。研究组和对照组的死亡率风险相似（比值比 [OR]，1.00；95%CI，0.91-1.09； = 0%）。在需要无创通气（OR，0.92；95%CI，0.83-1.03； = 0%）、需要机械通气（OR，0.64；95%CI，0.32-1.32； = 58%）和住院时间（平均差值，-0.42 天；95%CI，-1.95 至 1.11； = 62%）方面，研究组和对照组之间无显著差异。此外，秋水仙碱与胃肠道不良事件（OR，1.81；95%CI，1.56-2.11； = 0%）和腹泻（OR，2.12；95%CI，1.75-2.56； = 9%）的风险显著增加相关。
秋水仙碱不能改善 COVID-19 患者的临床结局，因此不支持在 COVID-19 患者的治疗中额外使用秋水仙碱。
秋水仙碱不能降低 COVID-19 患者的死亡率。在需要无创通气、需要机械通气和住院时间方面，秋水仙碱与对照药物之间无显著差异。秋水仙碱与胃肠道不良事件的风险增加相关。
